PURPOSE: Long-term clinical outcome data have established imatinib 400 mg/d as standard front-line treatment for newly diagnosed patients with chronic myeloid leukemia (CML). PATIENTS AND METHODS: The Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) trial is a multicenter study of imatinib 400 mg twice a day as initial therapy in 115 patients (70% Sokal low risk) with newly diagnosed CML in chronic phase who were observed for both molecular and cytogenetic responses for up to 18 months. Eighty-three patients (72%) completed the study, 10 patients (9%) discontinued the study because of adverse events, and six patients (5%) discontinued because of unsatisfactory therapeutic effect. RESULTS: Polymerase chain reaction analysis demonstrated rapid kinetics of major molecular response (MMR), with 48% of patients achieving MMR by 6 months, 54% by 12 months, and 63% by 18 months. Corresponding complete molecular response rates were 39%, 44%, and 55%, respectively. Median dose-intensity was 98%. Overall, 79% of patients who received at least 90% dose-intensity achieved MMR. The most frequent adverse events included myelosuppression, rash, fatigue, and musculoskeletal symptoms. CONCLUSION: This study suggests that imatinib 400 mg twice a day results in more rapid reduction in tumor burden than imatinib 400 mg/d with minimal added toxicity.
PURPOSE: Long-term clinical outcome data have established imatinib 400 mg/d as standard front-line treatment for newly diagnosed patients with chronic myeloid leukemia (CML). PATIENTS AND METHODS: The Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) trial is a multicenter study of imatinib 400 mg twice a day as initial therapy in 115 patients (70% Sokal low risk) with newly diagnosed CML in chronic phase who were observed for both molecular and cytogenetic responses for up to 18 months. Eighty-three patients (72%) completed the study, 10 patients (9%) discontinued the study because of adverse events, and six patients (5%) discontinued because of unsatisfactory therapeutic effect. RESULTS: Polymerase chain reaction analysis demonstrated rapid kinetics of major molecular response (MMR), with 48% of patients achieving MMR by 6 months, 54% by 12 months, and 63% by 18 months. Corresponding complete molecular response rates were 39%, 44%, and 55%, respectively. Median dose-intensity was 98%. Overall, 79% of patients who received at least 90% dose-intensity achieved MMR. The most frequent adverse events included myelosuppression, rash, fatigue, and musculoskeletal symptoms. CONCLUSION: This study suggests that imatinib 400 mg twice a day results in more rapid reduction in tumor burden than imatinib 400 mg/d with minimal added toxicity.
Authors: J P Radich; T Gooley; E Bryant; T Chauncey; R Clift; L Beppu; S Edmands; M E Flowers; K Kerkof; R Nelson; F R Appelbaum Journal: Blood Date: 2001-09-15 Impact factor: 22.113
Authors: Michele Baccarani; Giuseppe Saglio; John Goldman; Andreas Hochhaus; Bengt Simonsson; Frederick Appelbaum; Jane Apperley; Francisco Cervantes; Jorge Cortes; Michael Deininger; Alois Gratwohl; François Guilhot; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Dietger Niederwieser; Richard Silver; Rudiger Hehlmann Journal: Blood Date: 2006-05-18 Impact factor: 22.113
Authors: Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson Journal: N Engl J Med Date: 2006-12-07 Impact factor: 91.245
Authors: Moshe Talpaz; Richard T Silver; Brian J Druker; John M Goldman; Carlo Gambacorti-Passerini; Francois Guilhot; Charles A Schiffer; Thomas Fischer; Michael W N Deininger; Anne L Lennard; Andreas Hochhaus; Oliver G Ottmann; Alois Gratwohl; Michele Baccarani; Richard Stone; Sante Tura; Francois-Xavier Mahon; Sofia Fernandes-Reese; Insa Gathmann; Renaud Capdeville; Hagop M Kantarjian; Charles L Sawyers Journal: Blood Date: 2002-03-15 Impact factor: 22.113
Authors: Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker Journal: N Engl J Med Date: 2003-03-13 Impact factor: 91.245
Authors: Tim P Hughes; Jaspal Kaeda; Susan Branford; Zbigniew Rudzki; Andreas Hochhaus; Martee L Hensley; Insa Gathmann; Ann E Bolton; Iris C van Hoomissen; John M Goldman; Jerald P Radich Journal: N Engl J Med Date: 2003-10-09 Impact factor: 91.245
Authors: Andreas L Petzer; Dominic Fong; Thomas Lion; Irina Dyagil; Zvenyslava Masliak; Andrija Bogdanovic; Laimonas Griskevicius; Sandra Lejniece; Stefan Goranov; Liana Gercheva; Aleksandar Stojanovic; Dontcho Peytchev; Nikolay Tzvetkov; Rasa Griniute; Atanas Stanchev; Thomas Grubinger; Marthin Kwakkelstein; Peter Schuld; Guenther Gastl; Dominik Wolf Journal: Haematologica Date: 2012-04-17 Impact factor: 9.941
Authors: Wendy Deenik; Jeroen J W M Janssen; Bronno van der Holt; Gregor E G Verhoef; Willem M Smit; Marie José Kersten; Simon M G J Daenen; Leo F Verdonck; Augustin Ferrant; Anton V M B Schattenberg; Pieter Sonneveld; Marinus van Marwijk Kooy; Shulamit Wittebol; Roelof Willemze; Pierre W Wijermans; H Berna Beverloo; Bob Löwenberg; Peter J M Valk; Gert J Ossenkoppele; Jan J Cornelissen Journal: Haematologica Date: 2009-12-16 Impact factor: 9.941
Authors: Michael W Schmitt; Justin R Pritchard; Scott M Leighow; Bella I Aminov; Lan Beppu; Daniel S Kim; J Graeme Hodgson; Victor M Rivera; Lawrence A Loeb; Jerald P Radich Journal: Clin Cancer Res Date: 2018-07-24 Impact factor: 12.531
Authors: Tariq I Mughal; Omar Abdel-Wahab; Raajit Rampal; Ruben Mesa; Steffen Koschmieder; Ross Levine; Rüdiger Hehlmann; Giuseppe Saglio; Tiziano Barbui; Richard A Van Etten Journal: Leuk Lymphoma Date: 2016-05-31
Authors: Jorge E Cortes; Michele Baccarani; François Guilhot; Brian J Druker; Susan Branford; Dong-Wook Kim; Fabrizio Pane; Ricardo Pasquini; Stuart L Goldberg; Matt Kalaycio; Beatriz Moiraghi; Jacob M Rowe; Elena Tothova; Carmino De Souza; Marc Rudoltz; Richard Yu; Tillmann Krahnke; Hagop M Kantarjian; Jerald P Radich; Timothy P Hughes Journal: J Clin Oncol Date: 2009-12-14 Impact factor: 44.544
Authors: Tariq I Mughal; Jerald P Radich; Michael W Deininger; Jane F Apperley; Timothy P Hughes; Christine J Harrison; Carlo Gambacorti-Passerini; Giuseppe Saglio; Jorge Cortes; George Q Daley Journal: Haematologica Date: 2016-05 Impact factor: 9.941